lansoprazole has been researched along with pyrazines in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Y; Hao, S; Sun, J; Sun, X; Tian, X; Zhang, Z | 1 |
| Gottschalk, M; Griffin, KJ; Kyllo, JH; Rabinovitch, A; Thompson, PA | 1 |
1 trial(s) available for lansoprazole and pyrazines
| Article | Year |
|---|---|
Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Lansoprazole; Male; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; United States | 2014 |
1 other study(ies) available for lansoprazole and pyrazines
| Article | Year |
|---|---|
Lansoprazole enhances the antidiabetic effect of sitagliptin in mice with diet-induced obesity and healthy human subjects.
Topics: Adult; Animals; Area Under Curve; Blood Glucose; C-Peptide; Diet; Drug Synergism; Drug Therapy, Combination; Glucose; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Lansoprazole; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Pyrazines; Sitagliptin Phosphate; Triazoles | 2014 |